Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4163MR)

This product GTTS-WQ4163MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4163MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7785MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ14424MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ12338MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ11887MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ11112MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ2717MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ859MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ4770MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW